SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares of 19.93M shares in Q1 FY2026
Q1 FY2026 weighted avg shares was 19.93M shares.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 33.43M USD
- Year-over-year change
- —
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.43M | — |
Weighted Avg Shares vs competitors
How SGP compares with its peers on the latest reported figures
- SGP's FY2025 weighted avg shares of 33.43M shares is the lowest of the 10 companies compared; the peer median is 57.84M shares.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 486.05M | -1.7% | +0.2% | |
| LTM Jun 2026 | 355.23M | +0.8% | +0.4% | |
| LTM Mar 2026 | 200.88M | +19.9% | +34.5% | |
| LTM Mar 2026 | 77.28M | +27.7% | +25.2% | |
| LTM Jun 2026 | 57.84M | +3.1% | +6.4% | |
| LTM Mar 2026 | 54.96M | +27.5% | +16.9% | |
| LTM Mar 2026 | 52.81M | +4.4% | +2.9% | |
| LTM Apr 2026 | 49.63M | +0.8% | +1.1% | |
| LTM Mar 2026 | 41.05M | +3.2% | +14.2% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | 33.43M | — | — |
| Peer median (excluding SGP) | 57.84M | +3.2% | +6.4% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.